Chemical Name |
BVT 2733 |
CAS Number |
376640-41-4 |
MDL Number |
MFCD13152133 |
Molecular Formula |
C17H22Cl2N4O3S2 |
Molecular Weight |
465.42 |
Introduction of 376640-41-4 :
BVT 2733 is a potent, selective, and orally active non-steroidal 11β-hydroxydehydrogenase 1 (11β-HSD1) inhibitor. BVT 2733 is potently against the mouse enzyme (IC50=96 nM) over the human enzyme (IC50=3341 nM). BVT 2733 has the potential for the study of arthritis and obesity related disease[1]. IC50 & Target: IC50: 96 nM (mouse 11β-HSD1)
IC50: 3341 nM (human 11β-HSD1)[1] In Vitro: BVT 2733 (100 μM; 24 hours) co-treatment with PA (100 µM) reduces MCP-1 expression in fully differentiation adipocytes[3].
BVT 2733 (50-100 μM; 24 hours) reduces the inflammation protein levels (MCP-1, IL-6) in medium in J774.1 macrophages by Elisa[3].
In Vivo: BVT-2733 (oral administration; 100 mg/kg; twice daily; 2 weeks) attenuates the arthritis severity and anti-CII level and decreases the levels of serum TNF-α, IL-1β, IL-6 and IL-17 in CIA mice[2].
BVT 2733 (oral administration; 100 mg/kg; dosed (09.00 and 17.00 h); last 4 weeks) exhibits decreased body weight and enhanced glucose tolerance and insulin sensitivity when it compares to control mice. It also down-regulated the expression of inflammation-related genes including monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNF-α) and the number of infiltrated macrophages within the adipose tissue in vivo[3].
Purity |
NLT 98% |
Storage |
at 20ºC 2 years |
*The above information is for reference only.